XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Collaboration and License Agreement (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 46 Months Ended
Nov. 22, 2020
USD ($)
program
obligation
target
Dec. 31, 2022
USD ($)
Nov. 30, 2020
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
program
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Deferred revenue, revenue recognized       $ 16,959,000 $ 25,439,000 $ 45,199,000 $ 55,807,000    
Total revenues       35,290,000 42,569,000 $ 119,222,000 142,540,000    
BMS | Collaboration and License Agreement                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Number of biological targets | target 5                
Number of wholly owned programs | program 2                
Number of oncology targets | program 2                
Number of programs under agreement | program 5         1      
Upfront fee received   $ 55,000,000.0 $ 55,000,000.0            
Maximum milestone payments to be received $ 482,000,000.0                
Number of remain milestone payment targets | target 1                
Number of performance obligations | obligation 1                
Transaction price $ 55,000,000.0                
Total revenues       1,100,000 $ 11,200,000 $ 10,100,000 $ 40,000,000.0    
Deferred revenue       3,600,000   3,600,000   $ 3,600,000 $ 7,300,000
Receivable from collaboration       $ 0   $ 0   0 $ 0
BMS | Collaboration and License Agreement | Neurology and Immunology Product                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 257,000,000.0                
Milestone payments to be received upon achievement of certain specified commercial milestones $ 225,000,000.0                
BMS | Collaboration and License Agreement | Oncology, Neurology, and Immunology Product                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Deferred revenue, revenue recognized               $ 32,000,000.0